In this study, through high‐throughput screening of Kyn production in cancer cells using an FDA‐approved drug library, we found that lacidipine significantly inhibited kynurenine synthesis not only by suppressing the expression of IFN γ‐induced IDO1/2 and TDO2, but also by inhibiting the catalytic activity of IDO1. Here, IDO1 is linked to cancer.